The Trump administration is making good on its promise to reschedule cannabis, but only partially – raising plenty of questions for those in the cannabis industry.
Todd Blanche, the acting attorney general, signed an order last week that removes products sold under state medical cannabis licenses and FDA-approved cannabis products from schedule I – defined as substances with no accepted medical use, to schedule III – which includes legal but regulated substances including certain doses of Tylenol with codeine and ketamine.
